Nuvalent (NUVL) Stock Price, News & Analysis

Company Overview

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $77.04 to $79.03
• 50-Day Range: $67.38 to $88.96
• 52-Week Range: $61.80 to $113.51
• Volume: 428,656 shs
• Average Volume: 460,407 shs
• Market Capitalization: $5.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $113.10
• Consensus Rating: Moderate Buy

Nuvalent Stock Analysis - MarketRank™

Nuvalent scored higher than 39% of companies evaluated by MarketBeat, and ranked 686th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nuvalent has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nuvalent are expected to decrease in the coming year, from ($3.86) to ($4.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvalent is -22.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvalent is -22.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvalent has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.52% of the float of Nuvalent has been sold short.

Short Interest Ratio / Days to Cover

Nuvalent has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Nuvalent has recently increased by 1.46%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvalent does not currently pay a dividend.

Dividend Growth

Nuvalent does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.52% of the float of Nuvalent has been sold short.

Short Interest Ratio / Days to Cover

Nuvalent has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Nuvalent has recently increased by 1.46%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.21

News Sentiment

Nuvalent has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Nuvalent this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for NUVL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,437,464.00 in company stock.

Percentage Held by Insiders

12.52% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NUVL Stock Analysis - Frequently Asked Questions

How have NUVL shares performed this year?

Nuvalent's stock was trading at $78.28 on January 1st, 2025. Since then, NUVL stock has decreased by 1.5% and is now trading at $77.14.
View the best growth stocks for 2025 here.

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) released its quarterly earnings results on Thursday, February, 27th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.03) by $0.02.

When did Nuvalent IPO?

Nuvalent (NUVL) raised $151 million in an initial public offering on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share.

Who are Nuvalent's major shareholders?

Nuvalent's top institutional investors include Deerfield Management Company L.P. Series C (25.32%), Paradigm Biocapital Advisors LP (7.55%), Vanguard Group Inc. (6.33%) and Bain Capital Life Sciences Investors LLC (2.04%). Insiders that own company stock include Andrew A F Hack, James Richard Porter, Matthew Shair, Alexandra Balcom, Henry E Pelish, Darlene Noci, Deborah Ann Miller, Christopher Durant Turner and Emily Conley.
View institutional ownership trends.

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nuvalent own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvalent investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NUVL
• CIK: 1861560
• Web: www.nuvalent.com
• Phone: 857-357-7000
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $113.10
• High Stock Price Target: $135.00
• Low Stock Price Target: $97.00
• Potential Upside/Downside: +46.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-126,220,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -28.63%
• Return on Assets: -27.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.07
• Quick Ratio: 23.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.94 per share
• Price / Book: 7.05

Miscellaneous

• Outstanding Shares: 71,598,000
• Free Float: 62,157,000
• Market Cap: $5.52 billion
• Optionable: Optionable
• Beta: 1.42